Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Dermatologic 1Breast 1

Conditions

Triple Negative Breast Neoplasms 163Breast Neoplasms 162Carcinoma, Non-Small-Cell Lung 60Melanoma 44Ovarian Neoplasms 42Colorectal Neoplasms 37Carcinoma, Renal Cell 36Squamous Cell Carcinoma of Head and Neck 33Pancreatic Neoplasms 29Stomach Neoplasms 28Neoplasm Metastasis 27Uterine Cervical Neoplasms 24Neoplasms 24Endometrial Neoplasms 24Lung Neoplasms 19Head and Neck Neoplasms 19Esophageal Neoplasms 18Carcinoma, Transitional Cell 18Carcinoma, Hepatocellular 16Urinary Bladder Neoplasms 14Small Cell Lung Carcinoma 14Prostatic Neoplasms 14Parkinson Disease 4, Autosomal Dominant Lewy Body 13Sarcoma 10Mesothelioma 9Kidney Neoplasms 9Cholangiocarcinoma 9Carcinoma, Ovarian Epithelial 9Carcinoma, Merkel Cell 9Fallopian Tube Neoplasms 8

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Vaccinia × pembrolizumab × Breast × Clear all
NCT04725331 2025-11-21

A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors

Transgene

Phase 1/2 Terminated
31 enrolled
BreastDermatologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Sarcoma, Vaccinia, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡